Q1FY26 Mercedes-Benz/Suzuki flagship SDV naming and Tier 1 stress framing faded by Q4FY26.
- Other vertical fy27 — answer hedged.
- European auto data weak — answer hedged.
- China competition — answer hedged.
Other vertical growth in FY27; customer concentration
Manoj Raghavan: Healthcare and automotive double-digit growth FY27. Media & Communication wait and watch given visibility - difficult to commit. Will relook in Q3 and Q4. Auto and healthcare have multiple multimillion-dollar customers. Media has accounts but not seeing growth.
European auto data weak vs revival
Manoj Raghavan: Not looking at vehicle data. These are programs for next 2-3 years. German OEMs need to compete with China. Total cost of ownership lower needed. Most companies restarted investments. Not just older programs - new programs too. Europe focused on emission norms - 55% reduction vs 1990 by 2030 in place.
China competition impact
Manoj Raghavan: Not competing with Chinese - our customers are. Germany auto industry backbone of economy. German government will push and incentivize. As long as those companies exist needing to compete with China, we benefit. Very miniscule presence in China. China market different - lot of internal collaboration.
Healthcare last 2 quarters underperformance
Manoj Raghavan: Definitely next financial year double-digit growth. Won new deals/customers. H2 better than H1. Some projects rolling off, lacked continuity. Working on new customers, new businesses. Strengthening team delivery and sales. Healthcare primarily US with little Europe.
H2 growth vs Media slowdown; margin headwinds
Manoj Raghavan: H2 far better than H1. As revenues pick up, margin profile picks up. Utilization 70%, target 75% end of year. Will manage wage hike headwinds and show margin recovery vs H1.
Auto demand trajectory; cybersecurity incident impact; margin trajectory
Manoj Raghavan: Lot more confident about auto spend coming back. H2 definitely much better than H1. Europe definitely grow. Japan very positive. India pretty good. US still muted - coming quarter muted but adjacency aero/rail/off-road good traction. Cybersecurity at JLR - rather than quantifying, would have shown CC positive growth without it. Margin recovery slow but improving. H2 better than H1. Utilization 66% to 70%. Target 75% by end of FY26, 80% next year.
Auto H2 better; OEM spend areas; offshoring trend
Manoj Raghavan: H2 better only US clarification - all other markets good auto traction. Tata Elxsi known for offshoring - 30+ years experience. Areas: SDV, electrification, EVs, AD/ADAS, infotainment, cockpit. Revival in traditional powertrain ICE-related areas. Major markets: Europe #1, US #2, Japan, India significant. China relatively small.
Auto pickup over 4-6 quarters; margin walk; wage hikes
Gaurav Bajaj: 90 bps currency gain net cross-currency. Offset by 40 bps employee cost (campus onboarding final batch + sales strengthening). 30 bps other expenses (AI infrastructure partnerships). 20 bps operating margin uptick. PBT level 110 bps from hedging gains and UK R&D credit. Manoj Raghavan: Next year double-digit growth from transportation. Wage hikes - part of team in Q3, will wait till end of month given cybersecurity issue resolution.
Top customer normalcy emerging
Manoj Raghavan: Definitely seeing more positive conversations. People coming back for discussions. Were prepared for worst, things looking much better now.
Media bottomed out vs large deal one-off; attrition
Manoj Raghavan: Large deal ramp-ups happened. Growth will moderate in H2. Industry under stress with M&A and corporate action. Not projecting large H2 growth in this segment. Attrition gone up marginally - denominator going down increases ratio. Not significant. H2 better attrition expected.
Suzuki SDV deal size; vendor consolidation; Tier 1 stabilization; Comms volume commitments
Manoj Raghavan: Suzuki - first deal Pune ramped well. Recent deal cloud-based hardware/simulation in Trivandrum. Both 5-10 year deals. Peak headcount 6-8 quarters. Multi-year, multi-million dollar. Auto vendor consolidation deals - Tata Elxsi traditionally not strong. Multiple OEM deals announced - Mercedes, European OEM, Japanese OEM all ramping. Tier 1 - moved focus from Tier 1s to OEMs over 8 quarters. This quarter stabilized with maybe slight Tier 1 growth. Comms - commitment 3-year, achieved Q2 objectives, more to achieve in H2.
US holding back vs Europe; tariff impact on Europe; depreciation/tax
Nitin Pai: US doing very well on adjacency side - off-road, commercial vehicles, aerospace and defense. OEM side - new age OEMs and traditional OEMs. EV incentive withdrawal, emission norm relaxation - portfolio reset. New age OEMs - one or two winners well funded, others on horizon. Manoj Raghavan: Tariff causes Europe to look at best cost locations and outsourcing. Gaurav: Depreciation declining - no significant capex added, will continue declining slightly. Effective tax rate 26-26.5% full year, higher this quarter due to higher non-tax-exempted other income.
Bayer deal size
Manoj Raghavan: Marquee deal. Multi-year relationship at least 5 years. Competed with best in India, evaluated competition seriously, selected us. Multi-year, multi-million dollar deal. Stability for next 3 years if not more.
Semiconductor industry exposure
Nitin Pai: Not directly. Work with semiconductor platforms/partners. Software on top - Infineon, Qualcomm. No chip design intent. Software part contributes to topline. Important enabler for OEM engagements adopting platforms.
JLR cyber impact in Q2 auto growth; Q3/Q4 acceleration; fixed price jump
Manoj Raghavan: Without cyber impact would have been positive instead of -0.5% CC. Yes, Q3/Q4 acceleration expected. Fixed price - few fixed bid deals + system integration good revenue. H2 not big change in ratios.
Hyperscaler data center work; AI productivity vs innovation
Nitin Pai: Yes - have own mini-NVIDIA data center for AI experimentation. Dell award - infrastructure for on-prem data centers, AI workloads. Two parts: (1) AI/GenAI for productivity, quality, cost benefit; (2) innovation/features - ADAS, predictive analytics radiology/MRI. Not all GenAI - lot is AI. GenAI journey careful and calibrated re infringement/liability. Innovation features 14-15 years autonomous journey starting 2014. Yes work in cancer detection patterns.